Stockscreener 앱 받기
42.65
1.20%
-0.52
시간 외 거래:
41.89
-0.76
-1.78%
Definium Therapeutics Inc 주식(DFTX)의 최신 뉴스
DFTX Initiates Coverage On Wells Fargo -- Rating Set to Overweig - GuruFocus
Wells Fargo Initiates Definium Therapeutics at Overweight - marketscreener.com
DFTX Reiterated by Piper Sandler -- Price Target Raised to $73.0 - GuruFocus
Piper Sandler raises Definium stock price target on DT120 outlook By Investing.com - Investing.com South Africa
Piper Sandler raises Definium stock price target on DT120 outlook - Investing.com UK
Piper Sandler Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $73 - Moomoo
DEFINIUM THERAPEUTICS INC : PIPER SANDLER RAISES TARGET PRICE TO $73 FROM $48 - Bitget
Definium Therapeutics (DFTX) Highlights GAD Care Gaps, Is The Stock Already Overvalued? - Yahoo Finance
How New GAD Treatment Gap Data At Definium Therapeutics (DFTX) Has Changed Its Investment Story - Yahoo Finance
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
Definium Therapeutics Inc. (DFTX) Fundamental & Financial Data - Stocktwits
Definium Therapeutics Announces New Employee Inducement Grants - The Globe and Mail
Definium Therapeutics, Inc. (DFTX) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Why Is GH Research Stock Trading Higher on Thursday? - Benzinga
Analysts Are Bullish on Top Healthcare Stocks: Staar Surgical (STAA), Definium Therapeutics (DFTX) - The Globe and Mail
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology - Times Argus
Definium Therapeutics Inc. (DFTX) News, Articles, Events & Latest Updates - Stocktwits
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $63 - Moomoo
Is Definium Therapeutics, Inc. (DFTX) Stock a Biotech Opportunity After Positive DT120 Depression Trial Data? - Yahoo Finance
Definium Therapeutics (DFTX) Could Be 30% Overvalued After New GAD Study - Sahm
Wall Street Analysts Think Definium Therapeutics, Inc. (DFTX) Could Surge 32.42%: Read This Before Placing a Bet - Yahoo Finance
Definium Therapeutics, Inc. Announces Results from New Healthcare Claims Study of Treatment Patterns of Newly Diagnosed and Established Gad Patients, Including Pharmacotherapy Use, Discontinuation, Switching and Treatment Progression - marketscreener.com
Why is Definium Therapeutics stock rallying today? By Investing.com - Investing.com Nigeria
More Than Half of Newly Diagnosed GAD Patients Stopped Therapy - Stock Titan
Definium Therapeutics eyes key DT-120 depression data, advances anxiety program - MSN
DFTX Inc. Stock (DFTX) Opinions on Phase 3 Results and Offering - Moomoo
Why is Definium Therapeutics stock rallying today? - Investing.com
Definium Therapeutics (DFTX) Following Russell Index Removal And The Fair Value Debate - Sahm
Stifel Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $60 - Moomoo
Stifel raises Definium Therapeutics price target on MDD data By Investing.com - Investing.com Nigeria
Stifel raises Definium Therapeutics price target on MDD data - Investing.com
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering - AOL.com
Earnings call transcript: Definium’s Q1 2026 EPS miss overshadows strategic advances - Investing.com
Positive Phase 3 DT120 ODT Results in Depression Could Be A Game Changer For Definium Therapeutics (DFTX) - Sahm
Definium earnings on deck as pivotal psychedelic trial data looms By Investing.com - Investing.com India
DFTXDefinium Therapeutics Inc Volatility & Greeks - Finviz
1.97%
0.83%
자본화:
|
볼륨(24시간):